Adjunctive Treatment with Interferon Alpha 2b in Conjunctival Melanoma
Purpose: The aim of the study was to demonstrate the clinical outcomes after resection of conjunctival melanoma (CM) followed by topical interferon (IFN) alpha 2b after a long follow-up. Methods: Two consecutive CM patients were treated using tumor excision followed by topical IFN alpha 2b (1,000,00...
Gespeichert in:
Veröffentlicht in: | Ocular oncology and pathology 2022-06, Vol.8 (2), p.88-92 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 92 |
---|---|
container_issue | 2 |
container_start_page | 88 |
container_title | Ocular oncology and pathology |
container_volume | 8 |
creator | Huerva, Valentín Cid-Bertomeu, Pau Espinet, Ramón Canto, Luisa M. |
description | Purpose: The aim of the study was to demonstrate the clinical outcomes after resection of conjunctival melanoma (CM) followed by topical interferon (IFN) alpha 2b after a long follow-up. Methods: Two consecutive CM patients were treated using tumor excision followed by topical IFN alpha 2b (1,000,000 UI/mL) four times a day for 12 weeks. The second case presented positivity due to the presence of tumor cells in the lower margin of the resection. TNM staging was T1c, N0b, M0, and T1b in the first case and T1b, N0b, M0 in the second case. Follow-up was 72 and 71 months, respectively. Results: No side effects were observable after the administration of topical IFN alpha 2b. After extensive evaluation and imaging with computed tomography, no regrowth or distant metastasis was noticed during the follow-up period in both cases. Conclusions: IFN alpha 2b could be used as a co-adjuvant treatment after CM resection, in an attempt to reduce the possibility of recurrences. |
doi_str_mv | 10.1159/000522195 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_karge</sourceid><recordid>TN_cdi_karger_primary_522195</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>35959160</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3065-770ea410c10741b663ffa322110c691a831b9eb3b4fa0cd5ee17a90944f8446b3</originalsourceid><addsrcrecordid>eNptkM9LwzAUx4MobswdvIsEPHmoJs2PNhdhFKeDyTzMc0jbZOts05J2E_97I51FwdN7vPd53-_jC8AlRncYM3GPEGJhiAU7AeMwFDygnEWnQx_jEZi27c5jmArKGD8HI8IEE5ijMZjP8t3eZl1x0HDttOoqbTv4UXRbuLCddka72sJZ2WwVDFNYWJjU9nihSviiS2XrSl2AM6PKVk-PdQLe5o_r5DlYrp4WyWwZZARxFkQR0opilGEUUZxyToxRxH_vR1xgFROcCp2SlBqFspxpjSMlkKDUxJTylEzAQ6_b7NNK55l_1qlSNq6olPuUtSrk340ttnJTH6QIccwp8QK3vUDm6rZ12gy3GMnvPOWQp2evf5sN5E96HrjpgXflNtoNwGr12kvIJjeeuvqXOrp8AcLvhO4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Adjunctive Treatment with Interferon Alpha 2b in Conjunctival Melanoma</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Karger Journals</source><source>PubMed Central</source><creator>Huerva, Valentín ; Cid-Bertomeu, Pau ; Espinet, Ramón ; Canto, Luisa M.</creator><creatorcontrib>Huerva, Valentín ; Cid-Bertomeu, Pau ; Espinet, Ramón ; Canto, Luisa M.</creatorcontrib><description>Purpose: The aim of the study was to demonstrate the clinical outcomes after resection of conjunctival melanoma (CM) followed by topical interferon (IFN) alpha 2b after a long follow-up. Methods: Two consecutive CM patients were treated using tumor excision followed by topical IFN alpha 2b (1,000,000 UI/mL) four times a day for 12 weeks. The second case presented positivity due to the presence of tumor cells in the lower margin of the resection. TNM staging was T1c, N0b, M0, and T1b in the first case and T1b, N0b, M0 in the second case. Follow-up was 72 and 71 months, respectively. Results: No side effects were observable after the administration of topical IFN alpha 2b. After extensive evaluation and imaging with computed tomography, no regrowth or distant metastasis was noticed during the follow-up period in both cases. Conclusions: IFN alpha 2b could be used as a co-adjuvant treatment after CM resection, in an attempt to reduce the possibility of recurrences.</description><identifier>ISSN: 2296-4681</identifier><identifier>EISSN: 2296-4657</identifier><identifier>DOI: 10.1159/000522195</identifier><identifier>PMID: 35959160</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Case Series</subject><ispartof>Ocular oncology and pathology, 2022-06, Vol.8 (2), p.88-92</ispartof><rights>2022 S. Karger AG, Basel</rights><rights>Copyright © 2022 by S. Karger AG, Basel.</rights><rights>Copyright © 2022 by S. Karger AG, Basel 2022</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3065-770ea410c10741b663ffa322110c691a831b9eb3b4fa0cd5ee17a90944f8446b3</citedby><cites>FETCH-LOGICAL-c3065-770ea410c10741b663ffa322110c691a831b9eb3b4fa0cd5ee17a90944f8446b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218643/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218643/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,2427,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35959160$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huerva, Valentín</creatorcontrib><creatorcontrib>Cid-Bertomeu, Pau</creatorcontrib><creatorcontrib>Espinet, Ramón</creatorcontrib><creatorcontrib>Canto, Luisa M.</creatorcontrib><title>Adjunctive Treatment with Interferon Alpha 2b in Conjunctival Melanoma</title><title>Ocular oncology and pathology</title><addtitle>Ocul Oncol Pathol</addtitle><description>Purpose: The aim of the study was to demonstrate the clinical outcomes after resection of conjunctival melanoma (CM) followed by topical interferon (IFN) alpha 2b after a long follow-up. Methods: Two consecutive CM patients were treated using tumor excision followed by topical IFN alpha 2b (1,000,000 UI/mL) four times a day for 12 weeks. The second case presented positivity due to the presence of tumor cells in the lower margin of the resection. TNM staging was T1c, N0b, M0, and T1b in the first case and T1b, N0b, M0 in the second case. Follow-up was 72 and 71 months, respectively. Results: No side effects were observable after the administration of topical IFN alpha 2b. After extensive evaluation and imaging with computed tomography, no regrowth or distant metastasis was noticed during the follow-up period in both cases. Conclusions: IFN alpha 2b could be used as a co-adjuvant treatment after CM resection, in an attempt to reduce the possibility of recurrences.</description><subject>Case Series</subject><issn>2296-4681</issn><issn>2296-4657</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNptkM9LwzAUx4MobswdvIsEPHmoJs2PNhdhFKeDyTzMc0jbZOts05J2E_97I51FwdN7vPd53-_jC8AlRncYM3GPEGJhiAU7AeMwFDygnEWnQx_jEZi27c5jmArKGD8HI8IEE5ijMZjP8t3eZl1x0HDttOoqbTv4UXRbuLCddka72sJZ2WwVDFNYWJjU9nihSviiS2XrSl2AM6PKVk-PdQLe5o_r5DlYrp4WyWwZZARxFkQR0opilGEUUZxyToxRxH_vR1xgFROcCp2SlBqFspxpjSMlkKDUxJTylEzAQ6_b7NNK55l_1qlSNq6olPuUtSrk340ttnJTH6QIccwp8QK3vUDm6rZ12gy3GMnvPOWQp2evf5sN5E96HrjpgXflNtoNwGr12kvIJjeeuvqXOrp8AcLvhO4</recordid><startdate>20220601</startdate><enddate>20220601</enddate><creator>Huerva, Valentín</creator><creator>Cid-Bertomeu, Pau</creator><creator>Espinet, Ramón</creator><creator>Canto, Luisa M.</creator><general>S. Karger AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20220601</creationdate><title>Adjunctive Treatment with Interferon Alpha 2b in Conjunctival Melanoma</title><author>Huerva, Valentín ; Cid-Bertomeu, Pau ; Espinet, Ramón ; Canto, Luisa M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3065-770ea410c10741b663ffa322110c691a831b9eb3b4fa0cd5ee17a90944f8446b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Case Series</topic><toplevel>online_resources</toplevel><creatorcontrib>Huerva, Valentín</creatorcontrib><creatorcontrib>Cid-Bertomeu, Pau</creatorcontrib><creatorcontrib>Espinet, Ramón</creatorcontrib><creatorcontrib>Canto, Luisa M.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Ocular oncology and pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huerva, Valentín</au><au>Cid-Bertomeu, Pau</au><au>Espinet, Ramón</au><au>Canto, Luisa M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adjunctive Treatment with Interferon Alpha 2b in Conjunctival Melanoma</atitle><jtitle>Ocular oncology and pathology</jtitle><addtitle>Ocul Oncol Pathol</addtitle><date>2022-06-01</date><risdate>2022</risdate><volume>8</volume><issue>2</issue><spage>88</spage><epage>92</epage><pages>88-92</pages><issn>2296-4681</issn><eissn>2296-4657</eissn><abstract>Purpose: The aim of the study was to demonstrate the clinical outcomes after resection of conjunctival melanoma (CM) followed by topical interferon (IFN) alpha 2b after a long follow-up. Methods: Two consecutive CM patients were treated using tumor excision followed by topical IFN alpha 2b (1,000,000 UI/mL) four times a day for 12 weeks. The second case presented positivity due to the presence of tumor cells in the lower margin of the resection. TNM staging was T1c, N0b, M0, and T1b in the first case and T1b, N0b, M0 in the second case. Follow-up was 72 and 71 months, respectively. Results: No side effects were observable after the administration of topical IFN alpha 2b. After extensive evaluation and imaging with computed tomography, no regrowth or distant metastasis was noticed during the follow-up period in both cases. Conclusions: IFN alpha 2b could be used as a co-adjuvant treatment after CM resection, in an attempt to reduce the possibility of recurrences.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>35959160</pmid><doi>10.1159/000522195</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2296-4681 |
ispartof | Ocular oncology and pathology, 2022-06, Vol.8 (2), p.88-92 |
issn | 2296-4681 2296-4657 |
language | eng |
recordid | cdi_karger_primary_522195 |
source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Karger Journals; PubMed Central |
subjects | Case Series |
title | Adjunctive Treatment with Interferon Alpha 2b in Conjunctival Melanoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T09%3A01%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adjunctive%20Treatment%20with%20Interferon%20Alpha%202b%20in%20Conjunctival%20Melanoma&rft.jtitle=Ocular%20oncology%20and%20pathology&rft.au=Huerva,%20Valent%C3%ADn&rft.date=2022-06-01&rft.volume=8&rft.issue=2&rft.spage=88&rft.epage=92&rft.pages=88-92&rft.issn=2296-4681&rft.eissn=2296-4657&rft_id=info:doi/10.1159/000522195&rft_dat=%3Cpubmed_karge%3E35959160%3C/pubmed_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/35959160&rfr_iscdi=true |